A Phase 2 interventional study of Lasofoxifene and Placebo in Bone Loss, sponsored by Ligand Pharmaceuticals. Completed at 1 site in United Kingdom. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2011-08-10.
Sponsored by Ligand Pharmaceuticals · Phase 2, Interventional, and Basic science
The objective of the study is to demonstrate the effects that lasofoxifene has on serum markers of bone metabolism.
1,640 studies on the registry are indexed under Osteoporosis; 212 are open to participants now.
This study's enrollment of 51 is below the median of 95 across 1,133 interventional studies indexed under Osteoporosis.
Browse Osteoporosis studies →Ligand Pharmaceuticals is the lead sponsor of 21 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Lasofoxifene
Other: Placebo
Oral tablet, 0.25 mg, daily, 2 years
Matching placebo tablet given once daily for 2 years
Change in bone mineral density of the lumbar spine.
Time frame: 2 years
The secondary outcomes are the levels of cells and proteins in the blood that provide information about the health of bone, along with change in bone mineral density of the hip and forearm.
Time frame: 2 years
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ligand Pharmaceuticals